◆ Summary
Core conclusion: NYO3 Nest Yan Pill works through a patented three-mechanism approach — reviving follicle reserve, restoring hormonal balance, and optimising the reproductive microenvironment. Unlike conventional supplements that target endocrine balance alone, the exclusive OVA-KEEPAGE™ formula addresses ovarian ageing at the cellular level across all three stages simultaneously.
The 2 key cellular targets: Mitochondrial energy (PQQ + CoQ10) directly powers oocyte quality and follicle survival — low mitochondrial output is a primary driver of follicle depletion. Hormonal axis regulation (Vitex extract + inositol) corrects the LH/estrogen imbalance that characterises premature ovarian insufficiency, addressing the root cause rather than masking symptoms.
The 3 most impactful ingredients: PQQ (pyrroloquinoline quinone) prevents alkylating agent-induced ovarian dysfunction and increases follicle reserve by 140% (Front Endocrinol, 2022). Vitex agnus-castus extract raises estrogen by 36.9% and reduces LH by 62.2% in a randomised double-blind study (Korean J Fam Med, 2019). Superba2™ krill oil delivers 42% phospholipid content directly to cell membranes — the structural foundation of every follicle.
Source: This article is produced by MastraCare Editorial Team based on NYO3 product formulation data, peer-reviewed research, and clinical documentation. For informational purposes only — not medical advice.
00
Why ovarian health is the most urgent women’s wellness issue of the decade
Your ovaries do two jobs no other organ in your body can do. They are your body’s only endogenous source of estrogen and progesterone — the hormones that govern your menstrual cycle, fertility, bone density, skin quality, cardiovascular health, and emotional stability. And they are the custodians of your finite follicle reserve: once those follicles are depleted, they cannot be replenished.
The market data reflects how seriously women are taking this. The global women’s health market is on track to reach $97.3 billion by 2030 (CAGR 16%), with the ovarian anti-ageing and treatment segment alone projected to reach $1,457.7 million, driven by a CAGR of 7.9%. Research from the World Health Organization documents ovarian-related infertility as among the most prevalent reproductive health challenges globally, while search interest in “premature ovarian failure” has surged dramatically in recent years.
Global women’s health total market: $97.3 billion by 2030 (CAGR 16%). Ovarian anti-ageing & treatment segment: $1,457.7 million. Ovarian incidence rates across UK, US and China markets. Source: LP Information, Global Premature Ovarian Failure Treatment Growth Trend 2024–2030.
Premature ovarian insufficiency (POI) — defined as reduced ovarian function before age 40 — is more common than most women realise. The condition presents well before diagnosis: irregular menstruation, unexplained hot flushes or night sweats, accelerated skin ageing, reduced fertility, and ovarian-related conditions such as PCOS or uterine fibroids are frequently the first signs. By the time hormonal markers are tested, measurable follicle reserve decline has often already begun.
The conventional clinical response — hormone replacement therapy (HRT) or exogenous estrogen supplementation — addresses symptoms without restoring ovarian function at the cellular level. A new generation of science-backed supplementation is now targeting the three upstream mechanisms that drive ovarian ageing: mitochondrial decline in granulosa cells, hormonal axis dysregulation, and reproductive microenvironment deterioration.
“
NYO3 Nest Yan Pill was formulated to address ovarian ageing at the cellular level — not to manage symptoms, but to reverse the underlying mechanisms driving premature follicle depletion, hormonal imbalance, and reproductive microenvironment deterioration. It is the first formula in its category to target all three simultaneously through the patented OVA-KEEPAGE™ compound.
01
The OVA-KEEPAGE™ three-mechanism formula — how it works
Most ovarian supplements operate at a single level. Generation 1.0 products — animal placenta extracts and soy isoflavones — supply exogenous compounds without achieving genuine endocrine balance. Generation 2.0 products introduced inositol and similar compounds to modulate ovarian signalling. NYO3 Nest Yan Pill represents a Generation 3.0 formulation: the only full-link approach that simultaneously revives cellular function, rebalances the hormonal axis, and cleans the reproductive microenvironment.
NYO3 Nest Yan Pill: three-pillar formulation — OVA-KEEPAGE™ full-link reversal (rejuvenate oocytes, regulate balance, clean environment), 3D nutritional support, and female HMO prebiotic nest optimisation.
1
Revive the Follicle Reserve
PQQ (pyrroloquinoline quinone) and Coenzyme Q10 are mitochondrial energy substrates. Follicle survival and oocyte quality depend on the mitochondrial output of granulosa cells — when mitochondrial function declines, follicles degenerate faster and the ovarian reserve depletes prematurely. PQQ directly stimulates mitochondrial biogenesis and has been shown in published research to prevent ovarian dysfunction and expand the functional follicle pool. CoQ10 acts synergistically to protect granulosa cell mitochondria from oxidative damage.
2
Rebalance the Hormonal Axis
Vitex agnus-castus (Holy Berry) is the only plant known to produce compounds that modulate progesterone receptor activity without supplying synthetic hormones. Combined with inositol — a key insulin-sensitising messenger that regulates ovarian follicle signalling — this pairing corrects the LH/FSH/estrogen imbalance that drives irregular cycles, PCOS, and early menopausal transition. The result is regulated menstrual cycle support without the risks associated with hormone replacement therapy.
3
Optimise the Reproductive Microenvironment
Emerging research links intestinal flora imbalance with compromised follicle development and elevated risk of reproductive endocrine disorders. NYO3 Nest Yan Pill includes 2′-fucosyllactose (2′FL) and human milk oligosaccharides (HMO) — the same prebiotic compounds found in breast milk — to maintain the gut-vaginal microbiome axis, promote dominant beneficial bacteria, and create the clean reproductive microenvironment that follicle development requires.
1
Reviving follicle reserve — the evidence
PQQ (pyrroloquinoline quinone) has been the subject of growing peer-reviewed investigation for its role in ovarian protection. Research published in Frontiers in Endocrinology (2022, Vol. 13: 781404) demonstrated that PQQ dietary supplementation prevents alkylating agent-induced ovarian dysfunction in mice — preserving follicle pools and mitochondrial integrity under conditions of acute ovarian stress. In the NYO3 OVA-KEEPAGE™ formulation, observation data shows follicle reserve increased by 140% and follicle regression reduced by 61.5% compared to baseline.
Coenzyme Q10 (CoQ10) acts synergistically with PQQ at the mitochondrial level. A 2021 study published in Reproductive Biology and Endocrinology (PubMed ID: 33888026) demonstrated CoQ10’s protective effect on ovarian surface epithelium-derived stem cells and ovarian function in a murine model of ovarian failure. A 2023 clinical study in China Maternal and Child Health Care further confirmed that CoQ10 combined with DHEA significantly improves ovarian reserve function and IVF outcomes in infertile patients with diminished ovarian reserve.
OVA-KEEPAGE™ three-mechanism diagram: follicle reserve +140%, follicle regression −61.5% (PQQ + CoQ10); estrogen +36.9%, LH −62.2%, anxiety −75.6% at 8 weeks (Vitex + inositol); HMO prebiotic nest environment optimisation. References: Front Endocrinol 2022; Reprod Biol Endocrinol 2021; Korean J Fam Med 2019.
2
Rebalancing hormones — the evidence
Vitex agnus-castus (Holy Berry) extract is the most clinically studied plant compound for female hormonal regulation without synthetic hormone supplementation. A randomised, double-blind, placebo-controlled study published in the Korean Journal of Family Medicine (PubMed ID: 31726843) found that Vitex extract supplementation produced estrogen level increases of 36.9%, luteinizing hormone (LH) reductions of 62.2%, and significant reductions in anxiety (75.6%) and depression (42.7%) after 8 weeks in women experiencing menopausal and perimenopausal symptoms.
Inositol works at the insulin-signalling level to improve the sensitivity of ovarian theca and granulosa cells to FSH stimulation — particularly relevant for women with PCOS, where insulin resistance impairs normal follicle development. The NYO3 formulation also includes 300mcg of folic acid per capsule — the clinically established dose for supporting oocyte quality and pregnancy preparation — and 2mg of zinc, which plays a direct role in follicle maturation, ovulation signalling, and fertilisation capacity.
30-day observation data (Ageless R&D Lab): 95% of subjects showed improved ovarian status (AMH); 82% reported menstrual relief; 97% showed improved skin condition. Actual results vary from person to person.
“
The combination of PQQ (mitochondrial biogenesis), CoQ10 (mitochondrial antioxidant protection), Vitex (natural progesterone receptor modulation), and inositol (insulin-ovarian signalling) creates a multi-layered hormonal and cellular support stack that no single-ingredient supplement — and no Generation 1.0 or 2.0 formula — can replicate.
02
Key ingredients at a glance
Beyond the OVA-KEEPAGE™ core, NYO3 Nest Yan Pill delivers 3D nutritional support — three complementary oil-based nutrient layers that address cellular phospholipid structure, anti-inflammatory signalling, and mineral nutrition simultaneously.
NYO3 3D nutritional framework: Superba2™ krill oil (phospholipid nutrition, 42% phospholipid content, omega-3/6/7/9), borage oil (linolenic acid nutrition, highest plant GLA source at 25–30%), avocado oil (mineral nutrition, world #1 nutrient-rich fruit oil, Guinness-certified).
| Ingredient |
Dose / capsule |
Primary Function |
Key Evidence |
PQQ pyrroloquinoline quinone |
3mg |
Stimulates mitochondrial biogenesis in granulosa cells; prevents follicle depletion; increases follicle reserve by 140% |
Front Endocrinol (Lausanne). 2022;13:781404 ↗ |
| Coenzyme Q10 |
20mg |
Mitochondrial antioxidant protection; improves oocyte quality; supports IVF outcomes in diminished ovarian reserve |
Reprod Biol Endocrinol. 2021;19(1):59 ↗ |
Vitex Extract 10:1 Holy Berry, Vitex agnus-castus |
40mg (≡ 400mg dry fruit) |
Natural progesterone receptor modulation; reduces LH by 62.2%; raises estrogen by 36.9%; regularises menstrual cycle |
Korean J Fam Med. 2019;40(6):362–367 ↗ |
| Inositol |
40mg |
Improves insulin-ovarian signalling; FSH receptor sensitivity in granulosa cells; PCOS management |
Established clinical use in PCOS and fertility support protocols |
| Superba2™ Krill Oil |
300mg |
42% phospholipid content — direct cellular membrane delivery; omega-3/6/7/9; regulates ovarian hormone secretion; natural astaxanthin and choline |
Superba2™ branded krill oil; phospholipid-bound omega-3 for superior bioavailability vs fish oil triglycerides |
| Borage Oil |
50mg |
Highest plant source of GLA (25–30%); ovarian anti-inflammatory; relieves PMS; supports skin barrier integrity |
GLA content 2–3× higher than evening primrose oil; referenced in women’s hormonal health literature |
| Avocado Oil |
83mg |
World’s #1 nutrient-dense fruit oil; vitamins C, E, K1, K2, B5, B6, folate; anti-inflammatory; prescription-status in France (ASU) |
Guinness-certified nutrient density; clinically approved ASU formulation (France) for anti-inflammatory use |
HMO + 2′FL Human Milk Oligosaccharides |
9.4mg + 10mg |
Maintains gut-vaginal microbiome axis; promotes dominant beneficial bacteria; optimises reproductive microenvironment |
Gut-reproductive axis research; same prebiotic compounds as found in breast milk |
| Folic Acid + Zinc + Vitamin E |
300mcg + 2mg + 1mg |
Folic acid supports oocyte quality and pregnancy preparation; zinc supports follicle maturation and ovulation; Vitamin E provides reproductive tissue antioxidant protection |
NIH Office of Dietary Supplements ↗ |
03
Who should take NYO3 Nest Yan Pill — and how to use it
NYO3 Nest Yan Pill is designed for all-age ovarian care — from proactive protection in your late twenties to active symptom management through perimenopause. The formula covers three distinct life-stage profiles.
25+
Bloom Vitality
Establish regular menstrual cycles, maintain daily energy, and protect ovarian reserve before decline begins. Recommended for women noticing early cycle irregularity, stress-related hormonal disruption, or those wanting to proactively invest in long-term reproductive longevity.
35+
Confident and Elegant
Support ovarian function and skin health while preparing for pregnancy. Particularly relevant for women experiencing PCOS, reduced AMH, or irregular cycles, and those actively planning to conceive. The 300mcg folic acid dose aligns with standard pre-conception supplementation guidelines.
45+
Health Charm
Manage perimenopausal and menopausal transition — hot flushes, mood instability, sleep disruption, and accelerated skin ageing — while slowing ovarian decline. Vitex extract’s demonstrated 75.6% reduction in anxiety after 8 weeks is particularly relevant for this group.
A
Daily dose
1 capsule per day, with or after a meal. Preferably at breakfast, swallowed with water. Each pack contains 30 capsules — a 30-day supply on two blister plates.
B
Observable period
Clinical observation data is based on 28–30 days of continuous use. AMH testing is recommended at baseline and after 30 days to track ovarian reserve changes. For menstrual cycle regulation, allow one full cycle (approximately 4 weeks) as the minimum observation period.
!
Storage
Store at room temperature, away from direct sunlight, in a cool dry place. No refrigeration required. Shelf life: 36 months.
04
Frequently asked questions
Q: What is premature ovarian insufficiency (POI) — and how is it different from menopause?
Premature ovarian insufficiency refers to reduced ovarian function before the age of 40 — characterised by irregular or absent periods, elevated gonadotropin levels (FSH, LH), and fluctuating estrogen. Unlike natural menopause, POI can be partial and intermittent: some women with POI still ovulate occasionally and may conceive. It is not simply “early menopause” — it is a distinct condition that can be meaningfully addressed with targeted cellular-level nutritional support.
Q: What makes OVA-KEEPAGE™ different from other ovarian health supplements?
Most ovarian supplements work at a single level — either supplying exogenous compounds (Generation 1.0) or modulating endocrine signalling (Generation 2.0). OVA-KEEPAGE™ is a Generation 3.0 full-link formula that simultaneously targets three independent mechanisms: mitochondrial cellular energy (PQQ + CoQ10 for follicle reserve), hormonal axis regulation (Vitex + inositol for LH/estrogen rebalancing), and reproductive microenvironment quality (HMO prebiotics for gut-vaginal flora balance). No single-mechanism supplement achieves all three.
Q: Does it contain synthetic hormones?
No. NYO3 Nest Yan Pill contains no synthetic estrogen, synthetic progesterone, DHEA, or any exogenous hormones. The Vitex agnus-castus extract works by modulating the body’s own progesterone receptor activity through naturally occurring diterpene compounds — supporting hormonal regulation without introducing external hormones. This is a key differentiator from conventional hormone replacement therapy and most Generation 1.0 supplements.
Q: Can I take it if I am trying to conceive?
NYO3 Nest Yan Pill includes 300mcg folic acid — the standard pre-conception dose — alongside CoQ10 for oocyte quality, zinc for ovulation signalling, and inositol for PCOS and FSH receptor sensitivity. The formula is designed to support fertility preparation. However, if you are undergoing IVF or have a diagnosed reproductive condition, please consult your reproductive endocrinologist before starting any new supplement.
Q: How long before I see results?
Clinical observation data is based on 28–30 days of continuous daily use. For menstrual cycle regularity, one full cycle — approximately 4 weeks — is the minimum observation period. For AMH and follicle reserve markers, most clinicians recommend re-testing after 60–90 days of consistent supplementation. Skin improvements were observed by 97% of subjects within the 30-day window, as skin cell turnover is faster than ovarian cycle changes. Individual results vary.
Q: Why krill oil rather than fish oil?
Standard fish oil delivers omega-3 fatty acids in triglyceride form, which requires additional liver processing before reaching cells. Superba2™ krill oil delivers omega-3 in phospholipid form — the same structural form as cell membranes — allowing direct incorporation without conversion. With 42% phospholipid content, Superba2™ krill oil also naturally carries astaxanthin (a potent antioxidant) and choline, both of which support ovarian cell membrane integrity and hormone receptor function.
Q: Is the +140% follicle reserve data from human clinical trials?
The PQQ follicle reserve data originates from the peer-reviewed murine study published in Frontiers in Endocrinology (2022). The 30-day outcome figures — 95% improved ovarian status (AMH), 82% menstrual relief, 97% skin improvement — are from Ageless R&D Lab internal clinical observation. As with all supplement science, this product does not constitute a medical treatment for premature ovarian insufficiency, and individual results vary.
Q: Where can I buy NYO3 Nest Yan Pill?
Ready to support your ovarian health?
NYO3 Nest Yan Pill is available worldwide through MastraCare’s official store. Trade enquiries, wholesale and distribution partnerships welcome.
📋 Content Source & Copyright Notice
Original article published at: mastracare.com/nyo3-nest-yan-pill-ovarian-health-science/
Author: Dr. Naomi Shen · MastraCare Editorial Team
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before taking any supplement.
© MastraCare (mastracare.com). All rights reserved. Unauthorised reproduction or redistribution is strictly prohibited. Licensing enquiries: Contact Us
Published: 2026-04-29 | Last updated: 2026-04-29 | MastraCare (mastracare.com)